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Patients with chronic thromboembolic pulmonary hypertension (CTEPH) have poor prognosis, and pulmonary 
endarterectomy (PEA) is considered the treatment of choice for this condition. We report a case and review the 
literature of successful PEA for CTEPH due to antiphospholipid syndrome associated with systemic lupus 
erythematosus. The definitive and decisive approach needed to treat this high-risk patient with a history of comorbidity, 
long-term illness and poor compliance was found with a therapy of PEA.  
 




Antiphospholipid syndrome (APS) is characterized by venous or arterial thromboses accompanied by a persistence in 
antiphospholipid antibodies in patients’ serum, namely anticardiolipin (aCL), antibeta2GPI (anti-b2-GPI) or lupus 
anticoagulant (LA). Fifty per cent of APS patients have an associated connective tissue disease, mainly systemic lupus 
erythematosus (SLE) [1]. Pulmonary complications, especially pulmonary arterial hypertension (PAH), may aggravate 
both of these conditions: 0.5–14% in SLE [2] and 0.5% in APS [3]. PAH may be due to chronic pulmonary 
thromboembolism as a pulmonary manifestation of the APS. Chronic thromboembolic pulmonary hypertension 
(CTEPH) is defined as a mean pulmonary arterial pressure (PAP) greater than 25 mmHg persistent for more than 6 
months which occurs in 2–4% of patients after the diagnosis of pulmonary embolism [4]. CTEPH results in persistent 
vascular obstruction and vasoconstriction leading to further abnormal remodelling of the vessels. Patients with CTEPH 
have poor prognosis, and pulmonary endarterectomy (PEA) is considered the treatment of choice for this condition [4, 
5]. We report a case of successful PEA for CTEPH due to APS associated with SLE. Of note, the definitive and 
decisive approach needed to treat this highrisk patient with a history of comorbidity, long-term illness and poor 
compliance was found with a PEA therapy.  
 
Case report In 2009, a 30-year-old male patient with SLE and APS presented to our attention for further investigations 
for spontaneous lower extremity deep venous thrombosis (DVT) that had occurred 15 days earlier. At the time, the 
patient was being treated with low-molecular weight heparin (LMWH). The patient had been followed up from the age 
of 12 till the age of 28 by our centre, when he voluntarily interrupted any medical control and therapy. Past medical 
history was significant for a diagnosis of SLE when he was 12 with the following manifestations over the years: 
arthritis, leucopoenia, severe and prolonged thrombocytopenia (minimum 1,000/mm3 ), nephritis (not biopsy proven 
because of the haemorrhagic risk in the course of thrombocytopenia), serositis, positive serology for antinuclear 
antibodies (ANA), antiDNA, LA. The patient had been treated with multiple immunosuppressive therapies (steroids, 
intravenous immunoglobulin, cyclosporin, azathioprine, danazol, IV cyclophosphamide, mycophenolate). The diagnosis 
of APS was based on 2 episodes of DVT (at the age of 12 and 13) in triple positivity for antiphosholipid antibodies at 
high titre. The patient had been on oral anticoagulant therapy (OAT) since the age of 15. Of note, a 2-year-long period 
of complete autointerruption of immunosuppressive, OAT and followup occurred at the age of 23, which resulted in the 
reactivation of the autoimmune disease. Comorbidites included: arterial hypertension, obesity (BMI 39), osteoporosis, 
recurrent infections, prothrombin polymorphism, heterozygosity and homozygosity for the A1298C mutation in the 
MTHFR (methylenetetrahydrofolate reductase) gene. 
On admission, he reported suffering from exertional dyspnoea for the past 8 months, pain and swelling of the right 
lower limb due to the recent DVT. Physical examination revealed a blood pressure of 150/100 mmHg, heart rate of 120 
bpm and oxygen saturation in room air 94%. An ulcerated lesion with erythema and oedema in the lower third region of 
the right leg was present. A cardiopulmonary examination revealed a split of S2, holosystolic murmur at the left sternal 
border. The lungs were clear with respiratory sound reduced bilaterally. No hepatosplenomegaly was found. Laboratory 
and instrumental findings are shown in the Table 1. Based on these findings, the patient was diagnosed with CTEPH in 
APS. The patient denied rash, photosensitivity, fever, arthritis, mucosal ulcerations and chest pain. In the absence of 
signs or symptoms suggestive for lupus reactivation, the patient was treated with warfarin, with no immunosuppressive 
therapy. The patient was then discharged asymptomatic, with an estimated systolic PAP of 70 mmHg. After 6 months, 
we evaluated his cardiopulmonary parameters with non-invasive procedures. The angio-CT imaging concluded for the 
persistence of CTEPH despite full oral anticoagulation treatment. The patient was, therefore, referred to the CTEPH-
PEA Reference Center, where he completed the diagnostic work-up for a surgical evaluation (pulmonary arterial 
angiogram and right heart catheterization) (Table 1) which concluded for an operable CTEPH. Given the association of 
CTEPH with SLE and a thrombophilic tendency, a permanent inferior vena cava filter was placed before surgery. Thus, 
the patient underwent bilateral PEA (on the right: upper, median and lower lobes; on the left: lingular and lower lobes) 
(see Fig. 1). Surgery was performed through standard median sternotomy under total cardiopulmonary bypass. Some 
technical solutions were taken in order to reduce invasiveness. Given the APS [6], moderate hypothermia (23C) was 
preferred to deep hypothermia, and short periods (7 min) of intermittent circulatory arrest were performed, interrupted 
by periods ([5 min) of reperfusion, for a total circulatory arrest time of 67 min (27 min during right PEA and 40 min 
during left PEA). The patient’s course was uneventful, he was weaned from mechanical ventilation on postoperative 
day 1, and cycles of helmet cPAP were performed. The patient was discharged from the ICU on postoperative day 2. 
The results of the postoperative exams (Table 1) proved the success of the bilateral PEA (Fig. 1). The patient was 
dismissed asymptomatic on full oral anticoagulation therapy (target INR 3) on postoperative day 10. He continued 
regular follow-up at our centre. During the next months, no reactivation of SLE was observed. 15 months after surgery, 
the patient is asymptomatic (WHO functional class I) and the transthoracic echocardiogram proved the steady 
hemodynamic improvement, showing an estimated systolic PAP of 25 mmHg. Given the relief from cardiopulmonary 
symptoms, he was able to carry out physical activities and achieved a significant reduction of his BMI, from 39 to 30 
(starting from 108 to 85 kg). 
 
Discussion  
We report our experience in a case of resolutive PEA in a patient with CTEPH, in APS and SLE, previously not 
compliant to medical therapy. To our knowledge, in the previous 27 cases described (Table 2) none presented with 
inherited thrombophilic state associated with APS. Moreover, our patient was particularly complicated for the 
underlying chronic medical conditions, as metabolic syndrome and SLE. His SLE-state was diagnosed in paediatric age 
with major organ involvement and was treated with large cumulative doses of immunosuppressive drugs. The 
thromboprophylaxis in lupus patients with autoimmune thrombocytopenia and antiphosholipid antibodies may be a real 
challenge for physicians. In our case, the lower-dose prophylaxis used due to the concomitant severe and prolonged 
thrombocytopenia could explain the first thrombotic events at the age of 12 and 13. At the time of surgery, he had high 
anesthesiological risk for cardiac and pulmonary complications, thrombosis, infections and catastrophic antiphosholipid 
syndrome; favourable factors included low organ damage score and no lupus activity and immunosuppressive therapy at 
the time. Of note, in our patient, the diagnosis of CTEPH was made timely, and the patient was correctly evaluated and 
directed to a tertiary referral centre with a large experience, where PEA surgery and perioperative bridging therapy in a 
patient with high thrombotic risk were carefully and successfully performed. No serious perioperative complications 
occurred. After surgery, the hemodynamic and functional improvements were remarkable. This case confirms that a 
multidisciplinary diagnostic work-up and a collaborative clinical management are mandatory when surgical treatment is 
planned, especially, where major surgery is concerned. A further interesting aspect in our patient was his 
noncompliance to medical therapy which had twice led to the interruption of therapy and to the reactivation of lupus, 
and the second time also to an acute thromboembolic event. Non-adherence to medication regimen in SLE, especially in 
juvenile patients [7], is a very common problem [8], as in other chronic conditions, even more during the quiescent 
phases of the disease [9]. At the time of the transition to our adulthood care unit, attention was paid to establish a direct 
relationship with this young patient without parental intervention. Much time was spent trying to involve him directly, 
listening to his difficulties as well as explaining the goals and risks of the therapy involved. A good provider–patient 
relationship was consequently reached. In the subsequent years, close monitoring of medication intake and personal 
lifestyle adjustments were attempted. Probably, a low level of personal resources [10] could justify difficulties in 
finding motivation and promoting the use of active coping strategies to face distressful situations. Psychological support 
was refused by the patient. After surgery, a significant change in the patient’s attitude was noticed, and he is now aware 
of his current well-being and more conscious of the risks he has taken. This has determined a reinforcement of healthy 
behaviour and compliance aimed at better global functioning.  
 
Conclusions 
We reported a case of successful PEA for CTEPH due to APS associated with SLE. Of note, the PEA treatment 
represented in this experience a valid opportunity, in a patient at high risk because of comorbid, long-term illness and a 
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 Table 1 
clinical and laboratory findings on admission, after 6 months and post-PTEA 
 
                           
Laboratory data Normal: white cell and red cell counts, myocardial markers, 
complement, antiDNA, homocysteine. LA positive, aCL 
IgG/IgM 370/0, anti-β2-GPI IgG/IgM 156/0.D-dimer 1.82 
(<0.5); NT-proBNP 760 (<125 UI) 
Normal: white 













Normal: white cell 
and red cell counts 
myocardial markers 
NT-proBNP 540 
Arterial blood gas pH pO2 79 mm Hg, pCO2 29 mm Hg pH 7.41; 
pO2 82 mm Hg, 
pCO2 32 mm Hg 
No 
ECG Signs of chronic right ventricle overload: right-axis deviation, 
pulmonary P waves, incomplete right bundle branch block, 
and inverted T wave in leads V2–V5 





Overload of the right ventricle with tricuspid valve 
regurgitation and an estimated sPAP of 87 mmHg; LVEF 
59% with normal morphology and function 
sPAP 75 mm Hg; 
LVEF 56% 
sPAP 25 mmHg; 
LVEF 60% 
Lung scintigram Multiple perfusion defects in the right superior lobe and the 
left inferior lobe 
The perfusion 
ratio 53% on the 




between the two 
lungs. The 
perfusion ratio 34% 
on the left and 65% 
on the right 





Angio-CT scan Perfusion defects in the right proximal pulmonary artery, 
consistent with organized thrombus 
Complete 
occlusion of the 
right upper 





in the discendent 
branch. Reduced 
the changes in 
the discendent 












No Occlusion of the 
right upper lobe 
artery, reduced 
flow in the lower 
lobe and severe 
stenosis of the 







CO 4.52 L/min; 
PVR 885 





5.77 L/min (+28%); 
PVR 236 
dyne s cm−5(−73%); 
RVEF 39%. 
(+39%) 




























































Table 2 Case reports of PTEA for CTEPH in APS patients 
Author Year Number of 
patients 
Gender Age Notes 
Nakagawa 1992 1 M 43 CTEPH in aPL + 
Coignard 1995 1 M 25 CTEPH in APS 
Sandoval 1996 3 F 19 CTEPH in APS 
    
M 30 
  
    
F 40 Died in postoperative period 
Cucurull 1996 1 N/a N/a CTEPH in APS 
Ando 1998 5 M 44 APS 
    
F 22 APS in SLE 
    
F 56 APS 
    
M 21 APS 
    
M 38 APS 
Sato 2000 3 N/a N/a APS in SLE 
Kamezaki 2004 1 M 19 CTEPH in primary APS 
Peng 2006 1 F 19 CTEPH in previous APS and SLE diagnosed during 
Author Year Number of 
patients 
Gender Age Notes 
hospitalization for CTEPH 




TEA for CTEPH in APS has better prognosis than for CTEPH 
without APS (survival 56 mo vs. 33 mo) 
Porres- 
          
Aquilar 2008 1 M 40 CTEPH as first presentation of APS 
N/a not available 
 
